Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPOwER: Erenumab in episodic migraine
NCT03333109Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2018
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of erenumab in episodic migraine, sponsored by Novartis. Started Feb 2018; status: completed.
02
Drugs
erenumab
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT03333109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03333109.